title: [Promising new injection method to prevent angialgia/phlebitis from epirubicin hydrochloride therapy for breast cancer].
abstract: Epirubicin hydrochloride(EPI)is well known to cause phlebitis as a typical adverse drug reaction. By preventing the development of severe phlebitis, patients are expected to continue effective chemotherapy with EPI without a decrease in QOL. We have previously reported promising results of a new injection method to prevent phlebitis from occurring during EPI therapy thorough a prospective clinical trial in our hospital(Jpn J Cancer Chemother 36: 969-974, 2009). In the present study, we have compared the conventional injection method(EPI main -route method, n=15)with our new method, which has been consistently practiced at present(EPI sub -route method, n=77). We found that in the EPI main -route method, angialgia/phlebitis developed in 14 of 15 cases(Grade 3, 53. 3%), leading to alteration of the regimen in 3 cases. On the other hand, with the EPI sub -route method, incidence of angialgia/phlebitis was markedly decreased, and only 6 of 77 cases developed these adverse reactions(Grade 3, 0%). One possible explanation for these results is that the reduction of intimal stimulation by the EPI sub -route method might be caused by the dilution and washout of EPI with pre-medication, as well as the shortened infusion times of EPI. Therefore, on the basis of the above hypothesis, we conclude that the EPI sub-route method might be a more effective treatment for the expected prevention of angialgia/phlebitis.
authors.affiliation: Department of Nursing, Teikyo University Hospital.
authors.forename: Chiemi
authors.initials: C
authors.lastname: Ono
authors.forename: Mitsue
authors.initials: M
authors.lastname: Yamagami
authors.forename: Rika
authors.initials: R
authors.lastname: Kamatani
authors.forename: Makoto
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Tomoya
authors.initials: T
authors.lastname: Mukouyama
authors.forename: Masakazu
authors.initials: M
authors.lastname: Sugimoto
authors.forename: Taizan
authors.initials: T
authors.lastname: Suzuki
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kamo
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Seki
authors.forename: Kenji
authors.initials: K
authors.lastname: Eguchi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ikeda
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D010689:Phlebitis / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin